Locally Delivered 1% Metformin Gel in Peri-implantitis
- Conditions
- Peri-Implantitis
- Interventions
- Procedure: Placebo
- Registration Number
- NCT03312582
- Lead Sponsor
- King Saud University
- Brief Summary
This study evaluates the efficacy of 1% local metformin gel in deep periimplant pockets of type 2 diabetes mellitus patients. Half of the participants will receive 1% metformin gel with manual debridement while the other half will receive a placebo with manual debridement.
- Detailed Description
Metformin is an oral hypoglycemic drug categorized under biguanide and are considered the most efficient agents widely used in the treatment of type 2 diabetes mellitus.The general clinical benefits observed in therapy with MF seem to be greater than expected. They induce osteoblast cells to promote early bone formation through AMP kinase (AMPK) activity. Moreover, in a recent in vitro study, MF facilitated in the proliferation of MG63 osteoblast like cells. Thus, their action in stimulating bone formation has justified their use in the treatment of perimplantitis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
- Type 2 diabetes mellitus patients.
- Patients with peri-implantitis
- History of any other systemic diseases
- Cigarette smokers
- Smokeless tobacco users
- Patients who underwent scaling in the last 1 year
- Patients who took antibiotics in tje past 6 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Manual debridement and placebo Placebo - Manual debridement and 1% metformin gel 1% local metformin gel -
- Primary Outcome Measures
Name Time Method Peri-implant prpbing depth 6 months Will be measured with UNC-15 periodontal probe from crest of the gingival margin to the base of the peri-implant probing depth.
Marginal bone loss 6 months Marginal bone loss will be assessed on digital radiographs on calibrated computer screen.
- Secondary Outcome Measures
Name Time Method